Mettler-Toledo International Inc. MTD SPX

Healthcare · Diagnostics & Research · Switzerland

https://www.mt.com

Mettler-Toledo International Inc. manufactures and supplies precision instruments and services in the Americas, Europe, Asia, and internationally. It operates through five segments: U.S. Operations, Swiss Operations, Western European Operations, Chinese Operations, and Other Operations. The company offers laboratory instruments, such as laboratory balances, liquid pipetting solutions, real-time analytics, titrators, pH meters, process analytics sensors and analyzer technologies, density and refractometry instruments, and thermal analysis systems; and other analytical instruments, including UV/VIS spectrophotometers, moisture analyzers, and cell counters, as well as LabX, a laboratory software platform to manage and analyze data generated by its instruments and automate workflows. It also provides industrial instruments comprising industrial weighing instruments and related terminals, automatic dimensional measurement and data capture solutions, vehicle scale systems, industrial software, metal detectors, x-ray systems, checkweighers, and camera-based imaging equipment. In addition, the company offers retail weighing solutions consisting of weighing and software solutions, AI-driven image recognition solutions for fresh goods, and automated packaging and labeling solutions for the meat backroom. The company serves pharmaceutical and biotech companies, independent research organizations, and testing labs; food manufacturers and retailers; chemical, specialty chemicals, and cosmetics companies; transportation and logistics, metals, and electronics industries; and academic community through its direct sales force and indirect distribution channels. Mettler-Toledo International Inc. was incorporated in 1991 and is headquartered in Greifensee, Switzerland.

Market & Price

Market Cap

$23.86B

Current Price

$1,180.58

High / Low (52W)

$1,506.02 / $1,025.53

Beta

1.31

Valuation

Stock P/E

27.70

Industry PE

23.65

Forward P/E

23.02

PEG Ratio

2.48

Book Value

$-2.07

Price to Book

-569.50

P/S

5.83

EV/EBITDA

21.37

Dividend Yield

Profitability & Returns

ROCE

44.44%

ROE

ROA

20.57%

Profit Margin

21.40%

Op Margin

23.29%

EPS (Latest Qtr)

$8.33

EPS (TTM)

$42.62

Balance Sheet & Liquidity

Debt/Equity

Quick Ratio

0.69

Current Ratio

1.20

Debt

$2.23B

Total Assets

$3.71B

Current Assets

$1.36B

Working Capital

$164.55M

Ownership

Promoter Holding

0.43%

Chg in Prom Hold

FII / Inst Holding

103.22%

Chg in FII Hold

-0.01%

Financial Snapshot

Enterprise Value

$26.02B

Total Revenue (TTM)

$4.09B

EBITDA

$1.22B

Free Cash Flow

$615.04M

Operating Cash Flow

$901.12M

Shares Outstanding

20.21M

Gross Margin

59.19%

Payout Ratio

0.00%

Growth (CAGR)

Revenue 5Y

0.90%

Profit 5Y

-0.13%

Revenue (YoY)

7.20%

Earnings (YoY)

6.70%

PROS

Healthy ROCE of 44.4%.
Excellent profit margin of 21.4%.
Generates positive free cash flow.

CONS

Earnings shrank at -0.1% CAGR over 5 years.
In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	MTD Mettler-Toledo International Inc. SPX	1,180.58	27.70	$23.86B	-	44.44%	-	0.90%	-0.13%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
9	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%

Quarterly Results

Figures in USD.

Metric	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	660.82M	722.00M	734.85M	-	679.45M	731.37M	753.87M	-	649.16M	690.67M	807.36M	-	804.39M	924.35M	951.95M	-	897.79M	978.39M	985.85M	-	928.74M	982.12M	942.46M	925.95M	946.75M	954.53M	883.74M	983.22M	1.03B	1.13B	947.13M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	357.87M	403.35M	420.24M	454.30M	391.31M
Gross Profit	390.75M	299.91M	347.58M	369.49M	418.61M	343.39M	375.61M	400.98M	455.77M	374.93M	412.62M	419.25M	477.57M	388.32M	419.54M	435.06M	498.30M	374.41M	397.97M	469.61M	559.04M	471.70M	536.90M	555.82M	-	519.59M	571.66M	584.66M	-	546.57M	583.54M	559.54M	548.13M	565.67M	572.47M	525.88M	579.88M	609.46M	675.43M	555.82M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	306.34M	314.16M	319.56M	332.10M	329.21M
Operating Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	219.54M	265.71M	289.90M	343.34M	226.60M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	248.25M	295.89M	319.67M	379.23M	259.43M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	16.65M	16.78M	17.70M	17.39M	17.01M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	201.94M	248.66M	269.24M	329.07M	209.66M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	38.35M	46.31M	51.74M	43.31M	40.20M
Net Income	123.35M	65.67M	79.59M	101.33M	137.78M	92.47M	101.58M	104.95M	76.98M	93.30M	111.47M	126.65M	181.19M	111.81M	127.16M	129.40M	192.75M	98.11M	126.56M	161.77M	149.66M	149.66M	184.76M	203.69M	174.00M	174.00M	212.07M	220.60M	188.43M	188.43M	213.93M	201.63M	177.51M	221.81M	211.52M	163.59M	202.35M	217.49M	285.76M	169.45M
Diluted EPS	4.44	2.40	2.93	3.77	5.17	3.48	3.84	3.99	2.93	3.58	4.31	4.93	7.11	4.42	5.06	5.20	7.84	4.03	5.22	6.68	9.03	6.32	7.85	8.71	-	7.55	9.29	9.76	-	8.47	9.69	9.21	8.24	10.37	9.96	7.81	9.76	10.57	13.98	8.33
R&D Expense	-	28.97M	30.70M	30.14M	-	31.20M	32.58M	32.20M	-	34.71M	35.31M	34.84M	-	36.05M	36.58M	36.02M	-	34.39M	31.19M	34.66M	-	39.27M	42.60M	42.28M	-	43.03M	44.02M	44.13M	-	45.48M	47.24M	46.13M	46.41M	45.77M	47.12M	46.35M	49.28M	51.14M	-	51.27M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	-	2.94B	3.01B	3.09B	3.72B	3.92B	3.79B	3.87B	4.03B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.61B	1.55B	1.55B	1.64B
Gross Profit	993.08M	889.34M	1.04B	1.22B	1.24B	1.28B	1.36B	1.35B	1.44B	1.58B	1.68B	1.74B	1.80B	2.17B	2.31B	2.24B	2.33B	2.39B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.18B	1.16B	1.20B	1.27B
Operating Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.13B	1.08B	1.13B	1.12B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.24B	1.17B	1.24B	1.24B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	55.39M	77.37M	74.63M	68.52M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.07B	973.73M	1.04B	1.05B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	198.09M	184.95M	174.08M	179.72M
Net Income	202.78M	172.59M	232.15M	269.49M	290.85M	306.09M	338.24M	352.82M	384.37M	375.97M	512.61M	561.11M	602.74M	768.99M	872.50M	788.78M	863.14M	869.19M
Diluted EPS	5.79	5.03	6.80	8.21	9.14	9.96	11.44	12.48	14.22	14.24	19.88	22.47	24.91	32.78	38.41	35.90	40.48	42.05
R&D Expense	102.28M	89.69M	97.03M	116.14M	112.53M	116.35M	123.30M	119.08M	119.20M	128.31M	141.07M	143.95M	140.10M	169.77M	177.12M	185.28M	189.36M	199.37M

Compounded Sales Growth

5 Years:	0.90%
1 Year:	7.20%

Compounded Profit Growth

5 Years:	-0.13%
1 Year:	6.70%

Stock Price Performance

1 Year:	+2.17%
6 Months:	-21.61%
3 Months:	-13.62%
1 Month:	-4.80%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	1.72B	2.28B	2.11B	2.02B	2.15B	1.97B	1.96B	2.17B	2.55B	2.62B	2.79B	2.81B	-	3.49B	3.36B	3.24B	3.71B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.38B	1.23B	1.19B	1.36B
Cash & Equivalents	81.22M	78.07M	85.03M	447.58M	235.60M	101.70M	111.87M	85.26M	98.89M	158.67M	148.69M	178.11M	207.78M	94.25M	-	95.97M	69.81M	59.36M	66.89M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	441.69M	385.87M	342.27M	387.23M
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	709.32M	663.89M	687.11M	778.24M
Total Liabilities	-	-	1.01B	1.51B	1.42B	1.20B	1.22B	1.29B	1.38B	1.73B	2.00B	2.03B	2.37B	2.53B	-	3.47B	3.51B	3.37B	3.74B
Current Liabilities	-	-	494.68M	542.19M	609.84M	561.99M	564.19M	678.89M	558.21M	587.51M	689.67M	734.43M	754.51M	840.33M	-	1.15B	1.18B	1.17B	1.20B
Long Term Debt	-	-	203.59M	670.30M	476.71M	347.13M	395.96M	335.79M	575.14M	875.06M	960.17M	985.02M	1.24B	1.28B	-	1.91B	1.89B	1.83B	2.09B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.01B	2.08B	2.01B	2.15B
Total Equity	581.29M	503.25M	711.14M	771.58M	781.14M	827.22M	935.05M	719.60M	580.46M	434.94M	547.28M	590.06M	420.78M	282.68M	-	24.79M	-149.94M	-126.89M	-23.64M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	44.79M	44.79M	44.79M	44.79M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	223.15M	232.60M	268.28M	280.88M	327.70M	345.93M	418.91M	439.80M	460.76M	516.33M	565.00M	603.45M	724.70M	-	859.07M	965.87M	968.35M	955.77M
Investing Cash Flow	-48.70M	-72.58M	-77.02M	-132.29M	-97.26M	-86.02M	-94.32M	-100.75M	-231.46M	-217.34M	-138.94M	-99.08M	-100.36M	-	-139.40M	-131.69M	-119.46M	-193.87M
Financing Cash Flow	-178.53M	-157.44M	167.92M	-360.47M	-366.40M	-249.89M	-348.23M	-319.96M	-163.60M	-319.53M	-388.02M	-477.37M	-743.91M	-	-716.04M	-859.59M	-855.98M	-755.17M
Capital Expenditure	-61.01M	-60.04M	-73.94M	-98.50M	-95.59M	-82.35M	-89.39M	-82.51M	-123.96M	-127.43M	-142.73M	-97.34M	-92.49M	-	-121.24M	-105.32M	-103.90M	-107.12M
Free Cash Flow	162.14M	172.56M	194.34M	182.38M	232.12M	263.58M	329.52M	357.29M	336.80M	388.90M	422.28M	506.11M	632.21M	-	737.83M	860.55M	864.45M	848.65M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3.63M	-25.41M	-7.09M	6.72M
Share Buybacks	229.67M	5.99M	240.00M	204.58M	278.67M	294.98M	414.00M	494.97M	499.99M	400.00M	475.00M	775.00M	775.00M	1,000.00M	1.10B	900.00M	850.00M	800.00M

Ratios (Annual)

Figures in %.

Metric	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	57.4%	57.9%	58.4%	58.4%	58.9%	59.2%	60.1%	59.4%
Operating Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28.7%	28.5%	29.1%	27.8%
Net Margin %	-	-	-	-	-	-	-	-	-	-	17.5%	18.6%	19.5%	20.7%	22.3%	20.8%	22.3%	21.6%
ROE %	40.3%	24.3%	30.1%	34.5%	35.2%	32.7%	47.0%	60.8%	88.4%	68.7%	86.9%	133.3%	213.2%	-	3,519.1%	-526.1%	-680.2%	-3,677.4%
ROCE %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	48.0%	49.7%	54.4%	44.5%

Shareholding Pattern

Insiders

0.43%

Institutions

103.22%

Public Float

103.67%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	8.76%	1.77M	$2.09B
2	Vanguard Capital Management LLC	6.54%	1.32M	$1.56B
3	Capital International Investors	5.35%	1.08M	$1.28B
4	Vanguard Portfolio Management LLC	4.93%	996.08K	$1.18B
5	State Street Corporation	4.66%	942.53K	$1.11B
6	Alliancebernstein L.P.	3.75%	757.11K	$893.83M
7	T. Rowe Price Investment Management, Inc.	3.62%	732.05K	$864.25M
8	Bank Of New York Mellon Corporation	3.48%	703.48K	$830.51M
9	Geode Capital Management, LLC	3.00%	605.74K	$715.12M
10	Fundsmith LLP	2.81%	568.52K	$671.18M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for MTD

No recent headlines available.

MTD · Healthcare